Medpace(US:MEDP)2023-04-25 16:08Financial Performance - Q1 2023 - Revenue increased to $434.1 million, a 31.2% increase compared to $330.9 million in Q1 2022[4, 25] - EBITDA reached $92.8 million, a 31.9% increase from $70.4 million in Q1 2022[25] - Net income was $72.9 million, up 18.9% from $61.3 million in Q1 2022[25] - Diluted EPS increased to $2.27, a 34.3% increase compared to $1.69 in Q1 2022[25] Business Development - Net new business awards totaled $555.8 million, a 31.4% increase compared to $423.0 million in Q1 2022[4] - Net book-to-bill ratio was 1.28x[4] - Ending backlog reached $2,460.1 million, a 17.8% increase compared to $2,088.0 million in Q1 2022[4] - Backlog conversion rate was 18.6%[4] Financial Guidance - Full Year 2023 - Revenue is projected to be between $1,745 million and $1,805 million, representing a 19.5% to 23.6% year-over-year growth[67] - EBITDA is expected to be between $335 million and $355 million, representing an 8.7% to 15.2% year-over-year growth[67] - Net income is projected to be between $250 million and $269 million, representing a 1.9% to 9.6% year-over-year growth[67] - Diluted EPS is expected to be between $7.81 and $8.40, representing a 7.3% to 15.4% year-over-year growth[67]